Reveal Life Science

What it does

Reveal Life Science is a Montréal-based life-science technology platform that combines Raman spectroscopy with real-time artificial intelligence to provide molecular-level tissue characterization. Its flagship investigational product, the Sentry™ Surgical Platform, is designed to help surgeons distinguish cancerous from healthy tissue during operations. The system analyzes molecular signatures in seconds, aiming to reduce the need for repeat surgeries by ensuring complete tumor removal. The company also operates a research program called Reveal Biofluids, exploring non-invasive diagnostics using saliva, urine, and blood, and a cloud-based molecular intelligence ecosystem called Reveal Insight Atlas, which aggregates spectral data for AI model development.

Who it is for

The primary users are neurosurgeons and breast surgeons performing tumor resections. The Sentry™ Precision system targets brain tumor surgery, while the Sentry™ Scanner is intended for breast lumpectomy margin assessment. A third device, NaviSense™, is being developed for endoscopic procedures. Beyond surgery, the biofluid research program aims to serve clinicians, pharmacies, and remote healthcare providers with rapid, point-of-care diagnostics. The Insight Atlas platform is designed for researchers and health networks seeking to leverage molecular data for precision medicine.

Why it matters

Current surgical practice often relies on visual inspection and frozen section pathology, which can be slow or miss microscopic cancer cells. Reveal's technology provides real-time molecular feedback, potentially reducing the rate of positive margins and the need for additional surgeries. The company reports over 500 patients studied across 21 clinical trials, with accuracy exceeding 90% and FDA Breakthrough Device designation. By enabling faster, more precise tissue characterization, the platform could improve patient outcomes, lower healthcare costs, and expand access to advanced diagnostics in remote settings.

Launch signal

Reveal Life Science has achieved several notable milestones. It received FDA Breakthrough Device designation for its Sentry™ platform. In 2026, it won first place at the OVHcloud Startup Challenge at VivaTech and was featured on Radio-Canada's Découverte program. The company also announced a strategic partnership with IRCAD, a leading minimally invasive surgery research institute. These signals indicate growing regulatory and clinical traction, though the products remain investigational and not yet commercially available.

Brand and naming

The name "Reveal" directly communicates the core value proposition: making the invisible visible by revealing molecular information in real time. The tagline "Truth in Every Layer" reinforces the idea of precision and depth. The brand is positioned as a centralized R&D engine that spins out dedicated operating companies (e.g., Reveal Surgical) for commercialization, which is a clear and strategic structure. The visual identity uses clean, modern design with a focus on molecular imagery, aligning with its scientific and AI-driven narrative.